Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19178472 | PERSONALIZED WELLNESS SYSTEMS AND METHODS OF USE | April 2025 | September 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 19062053 | METHOD FOR DETERMINING ECOLOGICAL FLOW PROCESS AND WATER TEMPERATURE PROCESS OF HABITAT REQUIREMENTS OF FULL LIFE HISTORY OF FISH | February 2025 | August 2025 | Allow | 6 | 1 | 0 | No | No |
| 19029541 | METHODS OF DETECTING AND ENRICHING CIRCULATING TUMOR DNA | January 2025 | May 2025 | Allow | 4 | 1 | 0 | No | No |
| 18972561 | SYNTHESIZER COMPUTING MATRICES FOR PROTOCOL GENERATION | December 2024 | October 2025 | Abandon | 10 | 1 | 0 | No | No |
| 18901053 | PLASMA piRNA COMBINATION FOR EARLY DIAGNOSIS OF GASTRIC CANCER AND APPLICATION THEREOF | September 2024 | January 2026 | Allow | 16 | 2 | 1 | Yes | No |
| 18751165 | SYSTEM AND METHOD FOR CLEANING NOISY GENETIC DATA AND DETERMINING CHROMOSOME COPY NUMBER | June 2024 | June 2025 | Abandon | 12 | 1 | 0 | No | No |
| 18751187 | SYSTEM AND METHOD FOR CLEANING NOISY GENETIC DATA AND DETERMINING CHROMOSOME COPY NUMBER | June 2024 | April 2025 | Abandon | 10 | 1 | 0 | No | No |
| 18751158 | SYSTEM AND METHOD FOR CLEANING NOISY GENETIC DATA AND DETERMINING CHROMOSOME COPY NUMBER | June 2024 | April 2025 | Abandon | 10 | 1 | 0 | No | No |
| 18642389 | CANCER EVOLUTION DETECTION AND DIAGNOSTIC | April 2024 | December 2025 | Allow | 20 | 2 | 0 | No | No |
| 18633282 | SYSTEM AND METHOD FOR CLEANING NOISY GENETIC DATA AND DETERMINING CHROMOSOME COPY NUMBER | April 2024 | January 2026 | Allow | 22 | 2 | 1 | No | Yes |
| 18442036 | CANCER BIOMARKERS | February 2024 | March 2026 | Allow | 25 | 3 | 1 | No | No |
| 18431647 | MULTIPLE-TIERED SCREENING AND SECOND ANALYSIS | February 2024 | December 2024 | Allow | 11 | 2 | 0 | Yes | No |
| 18418045 | INTEGRATED METHOD FOR ARTHROPOD ACQUISITION, PROCESSING, IDENTIFICATION AND DETERMINATION OF PATHOGEN BURDEN | January 2024 | September 2025 | Allow | 20 | 1 | 0 | No | No |
| 18485119 | DATABASE PROCESSING SYSTEM FOR DETERMINING WHETHER AN ENTITY AFFECTS A TRANSITION | October 2023 | December 2024 | Allow | 14 | 3 | 0 | No | No |
| 18243569 | SYSTEM AND METHOD FOR CLEANING NOISY GENETIC DATA AND DETERMINING CHROMOSOME COPY NUMBER | September 2023 | February 2024 | Allow | 6 | 3 | 1 | No | No |
| 18274416 | METHOD AND SYSTEM FOR SEARCHING TARGET NODE RELATED TO QUERIED ENTITY IN NETWORK | July 2023 | February 2025 | Abandon | 18 | 2 | 0 | Yes | No |
| 18357799 | AUTOMATED METHODS OF DETECTING CELL FREE DNA | July 2023 | December 2024 | Allow | 17 | 2 | 1 | Yes | No |
| 18353737 | PERSONALIZED WELLNESS SYSTEMS AND METHODS OF USE | July 2023 | March 2025 | Allow | 20 | 5 | 1 | Yes | No |
| 18199144 | PROTEIN SEQUENCE AND STRUCTURE GENERATION WITH DENOISING DIFFUSION PROBABILISTIC MODELS | May 2023 | October 2025 | Allow | 29 | 4 | 1 | Yes | No |
| 18127566 | SYSTEMS AND METHODS FOR DETERMINING BREAST CANCER PROGNOSIS AND ASSOCIATED FEATURES | March 2023 | August 2025 | Allow | 28 | 3 | 1 | Yes | No |
| 17937797 | METHODS, SYSTEMS, AND COMPUTER READABLE MEDIA FOR MAKING BASE CALLS IN NUCLEIC ACID SEQUENCING | October 2022 | December 2025 | Allow | 38 | 1 | 0 | No | No |
| 17948221 | ATHLETE MANAGEMENT APPARATUS FOR MANAGING STATE OF ATHLETE IN CONJUNCTION WITH PROTECTOR WORN BY ATHLETE, ATHLETE MANAGEMENT SYSTEM, AND ATHLETE MANAGEMENT METHOD USING SAME | September 2022 | December 2024 | Allow | 27 | 1 | 0 | No | No |
| 17932124 | METHODS AND SYSTEMS FOR DETERMINING PERSONALIZED THERAPIES | September 2022 | July 2025 | Allow | 34 | 2 | 0 | Yes | No |
| 17883414 | AUTOMATED METHODS OF DETECTING CELL FREE DNA | August 2022 | April 2025 | Allow | 32 | 3 | 0 | Yes | No |
| 17857258 | SYSTEMS AND METHODS FOR LEVERAGING RELATEDNESS IN GENOMIC DATA ANALYSIS | July 2022 | March 2025 | Abandon | 32 | 3 | 0 | Yes | No |
| 17835862 | MOLECULAR PROFILING OF TUMORS | June 2022 | May 2025 | Allow | 35 | 3 | 1 | Yes | No |
| 17752681 | METHODS FOR TREATING ERECTILE DYSFUNCTION WITH A CGMP-SPECIFIC PHOSPHODIESTERASE 5 INHIBITOR PHARMACEUTICAL COMPOSITION | May 2022 | January 2026 | Abandon | 43 | 0 | 1 | No | No |
| 17682484 | METHODS AND SYSTEMS FOR EARLY SIGNAL ATTENUATION DETECTION AND PROCESSING | February 2022 | December 2022 | Allow | 9 | 2 | 0 | No | No |
| 17591907 | TUMOR ANTIGENICITY PROCESSING AND PRESENTATION | February 2022 | March 2026 | Allow | 49 | 2 | 0 | No | No |
| 17627672 | METHOD AND SYSTEM FOR ANALYZING PROSTATE BIOPSY | January 2022 | March 2025 | Allow | 38 | 2 | 0 | No | No |
| 17531426 | FILTERING GENETIC NETWORKS TO DISCOVER POPULATIONS OF INTEREST | November 2021 | December 2025 | Abandon | 49 | 1 | 0 | No | No |
| 17484786 | METHODS OF DISEASE ACTIVITY PROFILING FOR PERSONALIZED THERAPY MANAGEMENT | September 2021 | July 2025 | Allow | 46 | 3 | 0 | No | No |
| 17476113 | SYSTEMS AND METHODS FOR ANALYZING SEQUENCING DATA | September 2021 | November 2025 | Abandon | 50 | 2 | 0 | No | No |
| 17396084 | PREDICTION DEVICE BASED ON INTER-ORGAN CROSS TALK SYSTEM | August 2021 | November 2024 | Abandon | 39 | 2 | 0 | Yes | No |
| 17396165 | PREDICTION DEVICE BASED ON INTER-ORGAN CROSS TALK SYSTEM | August 2021 | November 2024 | Abandon | 39 | 2 | 0 | Yes | No |
| 17423550 | METHOD FOR PROVIDING SERVICE ON BASIS OF GENETIC INFORMATION ON USER GROUP, AND ELECTRONIC DEVICE THEREFOR | July 2021 | September 2025 | Allow | 50 | 2 | 0 | Yes | No |
| 17371378 | METHODS FOR DETECTING MUTATION LOAD FROM A TUMOR SAMPLE | July 2021 | July 2025 | Abandon | 48 | 2 | 0 | No | No |
| 17351216 | Bioinformatics Systems, Apparatuses, and Methods Executed on an Integrated Circuit Processing Platform | June 2021 | December 2025 | Allow | 54 | 2 | 1 | No | No |
| 17343552 | METHODS FOR DIAGNOSING INFECTIOUS DISEASE AND DETERMINING HLA STATUS USING IMMUNE REPERTOIRE SEQUENCING | June 2021 | June 2025 | Allow | 48 | 2 | 0 | Yes | No |
| 17328638 | METHODS, MEDIUMS, AND SYSTEMS FOR IDENTIFYING A GENE IN A FLOURESCENCE IN-SITU HYBRIDIZATION EXPERIMENT | May 2021 | August 2025 | Allow | 50 | 2 | 0 | Yes | No |
| 17295418 | METHOD FOR IDENTIFYING AN UNKNOWN BIOLOGICAL SAMPLE FROM MULTIPLE ATTRIBUTES | May 2021 | July 2025 | Abandon | 50 | 2 | 0 | No | No |
| 17308958 | Methods and Systems for Analyzing Nucleic Acid Molecules | May 2021 | May 2025 | Allow | 49 | 1 | 1 | Yes | No |
| 17238684 | MACHINE LEARNING SYSTEM FOR ASSESSING HEART VALVES AND SURROUNDING CARDIOVASCULAR TRACTS | April 2021 | October 2025 | Abandon | 54 | 1 | 0 | No | No |
| 17220105 | METHOD OF ESTABLISHING A CORONARY ARTERY DISEASE PREDICTION MODEL FOR SCREENING CORONARY ARTERY DISEASE | April 2021 | November 2024 | Abandon | 43 | 1 | 0 | No | No |
| 17215583 | System and Method for Analyte Monitoring and Predictive Modeling | March 2021 | July 2025 | Abandon | 52 | 2 | 0 | No | No |
| 17212799 | CODING ARCHITECTURES FOR AUTOMATIC ANALYSIS OF WAVEFORMS | March 2021 | May 2025 | Allow | 49 | 1 | 0 | Yes | No |
| 17165828 | Bioinformatics Systems, Apparatuses, and Methods for Performing Secondary and/or Tertiary Processing | February 2021 | December 2025 | Allow | 58 | 3 | 0 | Yes | No |
| 17165900 | Bioinformatics Systems, Apparatuses, and Methods for Performing Secondary and/or Tertiary Processing | February 2021 | April 2025 | Allow | 50 | 2 | 0 | Yes | No |
| 17150615 | INTEGRATED MACHINE-LEARNING FRAMEWORK TO ESTIMATE HOMOLOGOUS RECOMBINATION DEFICIENCY | January 2021 | November 2025 | Allow | 58 | 3 | 0 | Yes | No |
| 17260369 | METHOD FOR SETTING UP AN APPARATUS FOR BIOLOGICAL PROCESSES AND APPARATUS FOR BIOLOGICAL PROCESSES | January 2021 | August 2025 | Allow | 55 | 1 | 1 | No | No |
| 17124811 | Real Time Management of Data Relating to Physiological Control of Glucose Levels | December 2020 | October 2025 | Allow | 58 | 2 | 0 | No | No |
| 17252140 | POLYGENIC RISK SCORES FOR PREDICTING DISEASE COMPLICATIONS AND/OR RESPONSE TO THERAPY | December 2020 | July 2025 | Allow | 55 | 2 | 1 | No | No |
| 17101824 | MOLECULAR DATA STORAGE SYSTEMS AND METHODS | November 2020 | April 2025 | Allow | 52 | 1 | 0 | No | No |
| 17053955 | IMMUNE REPERTOIRE PATTERNS | November 2020 | November 2024 | Abandon | 48 | 1 | 1 | No | No |
| 17077967 | ANALYSIS OF GENETIC VARIANTS | October 2020 | July 2025 | Allow | 57 | 2 | 1 | Yes | No |
| 17032117 | Genomic Infrastructure for On-Site or Cloud-Based Dna and Rna Processing and Analysis | September 2020 | August 2025 | Allow | 59 | 3 | 1 | Yes | No |
| 16948162 | SYSTEMS AND METHODS FOR IDENTIFYING LIGHT EMITTING DROPLETS USING AN IMAGE SENSOR AND LENS SYSTEM | September 2020 | April 2025 | Allow | 55 | 1 | 1 | No | No |
| 17004104 | PROTEIN-TARGETED DRUG COMPOUND IDENTIFICATION | August 2020 | March 2026 | Allow | 60 | 3 | 1 | Yes | No |
| 17000109 | WORKFLOW FOR GENERATING COMPOUNDS WITH BIOLOGICAL ACTIVITY AGAINST A SPECIFIC BIOLOGICAL TARGET | August 2020 | January 2025 | Allow | 53 | 2 | 1 | Yes | No |
| 15733402 | METHOD FOR THE HARMONIZATION OF ASSAY RESULTS | July 2020 | October 2025 | Abandon | 60 | 3 | 0 | No | No |
| 16760199 | METHOD FOR ESTIMATING INFLAMMATION AREA OF PERIODONTAL POCKETS | July 2020 | November 2024 | Allow | 55 | 2 | 0 | Yes | No |
| 16919247 | SYSTEM AND METHOD FOR PROVIDING PATIENT-SPECIFIC DOSING AS A FUNCTION OF MATHEMATICAL MODELS UPDATED TO ACCOUNT FOR AN OBSERVED PATIENT RESPONSE | July 2020 | March 2025 | Abandon | 56 | 3 | 0 | No | Yes |
| 16918820 | SYSTEM AND METHOD FOR CLEANING NOISY GENETIC DATA AND DETERMINING CHROMOSOME COPY NUMBER | July 2020 | March 2024 | Allow | 45 | 3 | 1 | No | No |
| 16918756 | SYSTEM AND METHOD FOR CLEANING NOISY GENETIC DATA FROM TARGET INDIVIDUALS USING GENETIC DATA FROM GENETICALLY RELATED INDIVIDUALS | July 2020 | December 2025 | Allow | 60 | 3 | 1 | No | No |
| 16652755 | AUTOMATED PROCESS FOR INTERMEDIATE ORTHODONTIC DIGITAL SETUP GENERATION | April 2020 | February 2026 | Allow | 60 | 5 | 0 | Yes | No |
| 16825970 | Methods of Genomic Evaluation in Livestock | March 2020 | April 2025 | Abandon | 60 | 2 | 1 | No | No |
| 16738460 | Method for the Detection and Handling of Hypoglycemia | January 2020 | July 2025 | Allow | 60 | 4 | 1 | Yes | No |
| 16618571 | INCREMENTALLY OPTIMIZED PHARMACOKINETIC AND PHARMACODYNAMIC MODEL | December 2019 | July 2024 | Allow | 55 | 5 | 0 | No | No |
| 16664216 | CANCER BIOMARKERS | October 2019 | January 2024 | Allow | 51 | 4 | 1 | No | No |
| 16496196 | CANCER RISK BASED ON TUMOUR CLONALITY | September 2019 | December 2024 | Allow | 60 | 4 | 0 | No | No |
| 16538396 | BIOLOGICAL MATERIAL ANALYSIS METHOD, BIOLOGICAL MATERIAL ANALYSIS DEVICE, AND BIOLOGICAL MATERIAL ANALYSIS PROGRAM | August 2019 | November 2025 | Allow | 60 | 3 | 1 | No | No |
| 16452888 | ANALYSIS METHOD, INFORMATION PROCESSING APPARATUS, AND NON-TRANSITORY COMPUTER READABLE MEDIUM | June 2019 | January 2025 | Abandon | 60 | 3 | 1 | Yes | No |
| 16349820 | VALIDATION OF INFERRED ANTICANCER PATHWAYS | May 2019 | February 2023 | Allow | 45 | 6 | 0 | Yes | Yes |
| 14526041 | METHOD OF OVERCOMING THERAPEUTIC LIMITATIONS OF NONUNIFORM DISTRIBUTION OF RADIOPHARMACEUTICALS AND CHEMOTHERAPY DRUGS | October 2014 | June 2017 | Allow | 32 | 1 | 0 | Yes | No |
| 14059826 | BRIDGED ELEMENT FOR DETECTION OF A TARGET SUBSTANCE | October 2013 | March 2017 | Allow | 41 | 1 | 0 | No | No |
| 13922445 | RAPID BREEDING OF PLANTS | June 2013 | March 2017 | Allow | 45 | 1 | 1 | Yes | No |
| 13914174 | ANALYSIS OF DNA SAMPLES | June 2013 | February 2018 | Allow | 56 | 3 | 0 | Yes | No |
| 13829855 | Virtual Simulator Method and System for Neuromuscular Training and Certification via a Communication Network | March 2013 | August 2015 | Allow | 29 | 2 | 0 | No | No |
| 13771523 | Mobile Sampling of Target Substances | February 2013 | June 2015 | Allow | 28 | 2 | 0 | Yes | No |
| 13671754 | METHODS AND DEVICES FOR MANIPULATION OF TARGET CELLS USING A COMBINED APPLICATION OF ACOUSTICAL AND OPTICAL RADIATIONS | November 2012 | March 2015 | Allow | 28 | 1 | 1 | No | No |
| 13384227 | MEASURING CONTROL METHOD AND ARRANGEMENT | March 2012 | March 2014 | Allow | 26 | 2 | 0 | No | No |
| 13370699 | APPARATUS AND METHOD FOR GENERATING A CONDITION INDICATION | February 2012 | November 2015 | Allow | 45 | 2 | 0 | No | No |
| 13134267 | SELECTIVE RESONANCE OF CHEMICAL STRUCTURES | June 2011 | September 2012 | Allow | 16 | 1 | 1 | No | No |
| 13072877 | METHODS FOR DETERMINING THE RETENTION OF PEPTIDES IN REVERSE PHASE CHROMATOGRAPHY USING LINEAR SOLVENT STRENGTH THEORY | March 2011 | September 2013 | Allow | 30 | 2 | 1 | No | No |
| 12996190 | STIMULATING TASK PRESENTATION DEVICE AND STIMULATING TASK PRESENTATION METHOD FOR LIVING BODY OPTICAL MEASUREMENT APPARATUS | December 2010 | July 2013 | Allow | 32 | 1 | 0 | Yes | No |
| 12927906 | METHOD AND SYSTEM FOR OBTAINING IMPROVED DATA PERFUSION MEASUREMENTS | November 2010 | May 2012 | Allow | 18 | 1 | 0 | No | No |
| 12864876 | LIPID TUMOUR PROFILE | October 2010 | June 2015 | Allow | 59 | 1 | 2 | Yes | No |
| 12936434 | Ligands For The GLP-1 Receptor And Methods For Discovery Thereof | October 2010 | December 2013 | Allow | 38 | 2 | 1 | Yes | No |
| 12777140 | METHOD OF DIAGNOSING MILD OSTEOARTHRITIS | May 2010 | February 2013 | Allow | 34 | 1 | 0 | No | No |
| 12682800 | ESTIMATION OF DIAGNOSTIC MARKERS | April 2010 | September 2013 | Allow | 41 | 3 | 0 | No | No |
| 12709774 | METHOD FOR QUANTIFYING INITIAL CONCENTRATION OF NUCLEIC ACID FROM REAL-TIME NUCLEIC ACID AMPLIFICATION DATA | February 2010 | August 2012 | Allow | 30 | 2 | 1 | No | No |
| 12698996 | Environmental Monitoring of Microbe Metabolic Transformation | February 2010 | December 2012 | Allow | 34 | 1 | 1 | No | No |
| 12527888 | DETERMINATION OF QUALITY FEATURES IN AGRICULTURAL AND HORTICULTURAL CROPS | December 2009 | April 2013 | Allow | 44 | 2 | 1 | Yes | No |
| 12597479 | HAPLOTYPE ESTIMATING APPARATUS AND PROGRAM | October 2009 | November 2012 | Allow | 37 | 1 | 1 | No | No |
| 12576864 | PROTEOME EPITOPE TAGS AND METHODS OF USE THEREOF IN PROTEIN MODIFICATION ANALYSIS | October 2009 | September 2011 | Allow | 24 | 2 | 0 | No | No |
| 12534393 | Mobile Sampling of Target Substances | August 2009 | November 2012 | Allow | 40 | 2 | 1 | Yes | No |
| 12502725 | CONCURRENT OPTIMIZATION IN SELECTION OF PRIMER AND CAPTURE PROBE SETS FOR NUCLEIC ACID ANALYSIS | July 2009 | February 2011 | Allow | 19 | 1 | 0 | No | No |
| 12517552 | METHOD FOR ASSESSING DEGREE OF RELIABILITY OF NUCLEIC ACID BASE SEQUENCE | June 2009 | December 2011 | Allow | 30 | 1 | 0 | No | No |
| 12476907 | INDIVIDUALIZED RANKING OF RISK OF HEALTH OUTCOMES | June 2009 | November 2013 | Allow | 54 | 3 | 1 | No | No |
| 12351552 | Pharmaco-Genomic Mutation Labeling | January 2009 | March 2016 | Allow | 60 | 6 | 1 | No | Yes |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner LIN, JERRY.
With a 100.0% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 34.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner LIN, JERRY works in Art Unit 1685 and has examined 150 patent applications in our dataset. With an allowance rate of 88.0%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 54 months.
Examiner LIN, JERRY's allowance rate of 88.0% places them in the 68% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.
On average, applications examined by LIN, JERRY receive 3.01 office actions before reaching final disposition. This places the examiner in the 87% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by LIN, JERRY is 54 months. This places the examiner in the 2% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +9.5% benefit to allowance rate for applications examined by LIN, JERRY. This interview benefit is in the 41% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.
When applicants file an RCE with this examiner, 26.6% of applications are subsequently allowed. This success rate is in the 45% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 39.8% of cases where such amendments are filed. This entry rate is in the 61% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
This examiner withdraws rejections or reopens prosecution in 72.2% of appeals filed. This is in the 60% percentile among all examiners. Of these withdrawals, 38.5% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 65.5% are granted (fully or in part). This grant rate is in the 70% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 8.7% of allowed cases (in the 92% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 15.2% of allowed cases (in the 92% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.